c-MET tyrosine kinase inhibitors reverse multidrug resistance in breast cancer cells by targeting ABCG2 transporter
Journal of Pharmacy and Pharmacology · 2025
DOI: 10.1093/jpp/rgaf008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2025. Verfasst von Somayeh Nazari und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Hauptthemen laut MEDLINE: ATP Binding Cassette Transporter, Subfamily G, Member 2, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Breast Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Shiraz University of Medical Sciences.
Abstract (Originalsprache)
Background
Overcoming multidrug resistance (MDR), which is often caused by the overexpression of ATP binding cassette (ABC) transporters in cancer cells remains a major challenge for cancer treatment. Receptor tyrosine kinase inhibitors have demonstrated potential in reversing MDR. This study aimed to investigate the effects of c-MET RTKIs on the reversal of MDR induced by ABCG2 in breast cancer cells.
Methods
MTT assay was employed to assess antiproliferative activity of c-MET inhibitors, including cabozantinib, crizotinib, and PHA665752. The accumulation of the fluorescent probe mitoxantrone was evaluated by flow cytometry. The drug–drug interaction in combination treatments was analyzed using CalcuSyn software.
Results
The combination of cabozantinib, crizotinib, and PHA665752 with mitoxantrone resulted in synergistic effects in MDR cells. This was demonstrated by the mean CI values of 0.32 ± 0.07, 0.53 ± 0.05, and 0.59 ± 0.03, respectively. In the same cells, c-MET inhibitors enhanced the accumulation of mitoxantrone, with accumulation ratios ranging from 1.6 to 3.8, while no change was found in parental MCF-7 cells. Computational analysis revealed that the drug-binding region of ABCG2 transporters could be a viable target for these compounds. Conclusion c-MET inhibitors hold potential as effective agents for reversing MDR in ABCG2-medicated drug-resistant cancer cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
- Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
- Department of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University of Rome, P. le Aldo Moro 5, 00185 Rome, Italy.
ORCID-Profile: Fatemeh Moosavi
Förderung
- Shiraz University of Medical Sciences
Zitieren
APA
Nazari, S., Mosaffa, F., Poustforoosh, A., Saso, L., Firuzi, O., & Moosavi, F. (2025). c-MET tyrosine kinase inhibitors reverse multidrug resistance in breast cancer cells by targeting ABCG2 transporter. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgaf008
Vancouver
Nazari S, Mosaffa F, Poustforoosh A, Saso L, Firuzi O, Moosavi F. c-MET tyrosine kinase inhibitors reverse multidrug resistance in breast cancer cells by targeting ABCG2 transporter. Journal of Pharmacy and Pharmacology. 2025. doi:10.1093/jpp/rgaf008
BibTeX
@article{Nazari2025,
author = {Nazari, Somayeh and Mosaffa, Fatemeh and Poustforoosh, Alireza and Saso, Luciano and Firuzi, Omidreza and Moosavi, Fatemeh},
title = {c-MET tyrosine kinase inhibitors reverse multidrug resistance in breast cancer cells by targeting ABCG2 transporter},
journal = {Journal of Pharmacy and Pharmacology},
year = {2025},
doi = {10.1093/jpp/rgaf008}
}
EUVIMED